Wednesday, January 27, 2010

DDP 2010: Understand How Payers View and Manage the Medical Pipeline to Improve Product Value Calculations

Moderator: Stanton R. Mehr, Publisher, The Medical Pipeline
Steven Avey, Vice President, Managed Care, PartnerSrx
C. Daniel Mullins, PhD, Professor, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy
Scott Thompson, President, Pharmaceutical Practice, The Benfield Group
Raulo S. Frear, Pharm.D., Director, Pharmacy Services, The Regence Group

The Pharmaceutical Pipeline
There is an active pipeline development for compounds in the United States. Of the compounds in development, cancer is one of the top focuses. Are more compounds in the pipeline or are there slower approval rates by the FDA?

Product Value Categories of products on the market for Regence Rx: Effectiveness, safety, cost, persistency, convenience, me too product, no additional value. Over the last four years, the majority of the products have been classified as me too products or no additional value.

A few examples from the presentation:
Velaglucerase (Shire)
-What is it? Human cell line enzyme
-What does it do? Enzyme replacement therapy
-Likely indication: Type 1 Gaucher Disease

Data to date (8.3.2009)
-25 treatment native patients with Type 1 Gaucher disease
-2 doses administered
-Endpoints met (hemoglobin, platelet counts, spleen size)
-When do we expect to see it? 2Q-3Q, 2010
-What is the competition? Cerezyme (supply issues)

Fingolimond (Novartis)
-What is it? Immunosuppressant
-What does it do? Prevents egress of lymphocytes from lymph nodes
-Likely indication: Relapsing remitting multiple sclerosis

Share this article with your social network, just click below to share now!

No comments :

Post a Comment